Table 2.
Representative ongoing clinical trials of antiviral therapy for COVID-19.
| Registration number | Drug | Phase |
|---|---|---|
| ChiCTR2000030718/ChiCTR2000030054/ChiCTR2000029992/ChiCTR2000029988 | Chloroquine phosphate | IV |
| ChiCTR2000030704 | Bufonis venenum | IV |
| ChiCTR2000030702/ ChiCTR2000030627/ChiCTR2000030381/ChiCTR2000030312/ChiCTR2000030046/ChiCTR2000029975 | Convalescent plasma | 0 |
| ChiCTR2000030701 | Prolongin | 0 |
| ChiCTR2000030545/ChiCTR2000029954 | Honeysuckle oral liquid | IV |
| ChiCTR2000030535 | Ebastine | IV |
| ChiCTR2000030509 | NK Cells | 0 |
| ChiCTR2000030487/ChiCTR2000030424/ChiCTR2000030041/ChiCTR2000029853 | Azvudine | 0 |
| ChiCTR2000030480/ChiCTR2000030013 | Human interferon α1b | IV |
| ChiCTR2000030475 | Cytosorb | 0 |
| ChiCTR2000030442 | Combination of tocilizumab, IVIG and CRRT | 0 |
| ChiCTR2000030398 | Bismuth potassium citrate | N/A |
| ChiCTR2000030333 | Pirfenidone | 0 |
| ChiCTR2000030254/ChiCTR2000030113/ChiCTR2000029996 | Farpiravir | 0 |
| ChiCTR2000030218 | Combination of pinavir and ritonavir | N/A |
| ChiCTR2000030170 | Jakotinib hydrochloride | 0 |
| ChiCTR2000030167 | Recombinant human interleukin-2 | 0 |
| ChiCTR2000030138/ChiCTR2000030088/ChiCTR2000029990 | Human mesenchymal stem cells | II |
| ChiCTR2000030089 | Adalimumab | IV |
| ChiCTR2000030001 | Triazavirin | III |
| ChiCTR2000029898/ChiCTR2000029868/ChiCTR2000029761 | Hydroxychloroquine sulfate | IV |
| ChiCTR2000029741 | Chloroquine and lopinavir/ Ritonavir | IV |
| NCT04287686 | Recombinant human angiotensin-converting enzyme 2 | N/A |
| NCT04292899/NCT04292730/NCT04252664 | Remdesivir | III |
| NCT04305106/NCT04275414 | Bevacizumab | N/A |
| NCT04273529/NCT04273581 | Thalidomide | II |
| NCT04280588 | Fingolimod | II |
| NCT04261426 | Intravenous Immunoglobulin | II and III |
| NCT04306393/NCT04290871 | Nitric Oxide | II |
| NCT04252274 | Darunavir and obicistat | III |